Oncternal Therapeutics Inc (ONCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncternal Therapeutics Inc (ONCT) has a cash flow conversion efficiency ratio of -0.760x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.95 Million) by net assets ($9.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncternal Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2002–2023)
This chart illustrates how Oncternal Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ONCT total debt and obligations for a breakdown of total debt and financial obligations.
Oncternal Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncternal Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
-0.008x |
|
Foxtons Group Plc
LSE:FOXT
|
0.081x |
|
BioSenic S.A.
BR:BIOS
|
0.059x |
|
Trufin PLC
LSE:TRU
|
0.203x |
|
Golden Cross Resources Ltd
AU:GCR
|
-0.040x |
|
Calidi Biotherapeutics Inc.
NYSE MKT:CLDI
|
-0.589x |
|
Hynion AS
OL:HYN
|
0.061x |
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
0.029x |
Annual Cash Flow Conversion Efficiency for Oncternal Therapeutics Inc (2002–2023)
The table below shows the annual cash flow conversion efficiency of Oncternal Therapeutics Inc from 2002 to 2023. For the full company profile with market capitalisation and key ratios, see Oncternal Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $30.05 Million | $-32.16 Million | -1.070x | -77.78% |
| 2022-12-31 | $60.97 Million | $-36.70 Million | -0.602x | -99.52% |
| 2021-12-31 | $88.12 Million | $-26.59 Million | -0.302x | -94.81% |
| 2020-12-31 | $112.95 Million | $-17.50 Million | -0.155x | +86.76% |
| 2019-12-31 | $14.31 Million | $-16.75 Million | -1.170x | +22.35% |
| 2018-12-31 | $26.11 Million | $-39.35 Million | -1.507x | -145.76% |
| 2017-12-31 | $38.26 Million | $-23.46 Million | -0.613x | +41.30% |
| 2016-12-31 | $19.89 Million | $-20.78 Million | -1.045x | +90.31% |
| 2015-12-31 | $1.86 Million | $-20.04 Million | -10.777x | -568.13% |
| 2014-12-31 | $17.83 Million | $-28.76 Million | -1.613x | +60.81% |
| 2013-12-31 | $10.68 Million | $-43.97 Million | -4.116x | -429.03% |
| 2012-12-31 | $47.70 Million | $-37.11 Million | -0.778x | -68.98% |
| 2011-12-31 | $71.87 Million | $-33.09 Million | -0.460x | +21.99% |
| 2010-12-31 | $51.73 Million | $-30.53 Million | -0.590x | -111.23% |
| 2009-12-31 | $-8.75 Million | $-46.00 Million | 5.257x | +5854.26% |
| 2008-12-31 | $32.02 Million | $-2.92 Million | -0.091x | +80.84% |
| 2007-12-31 | $78.92 Million | $-37.63 Million | -0.477x | -303.85% |
| 2006-12-31 | $97.05 Million | $-11.46 Million | -0.118x | +75.05% |
| 2005-12-31 | $73.58 Million | $-34.82 Million | -0.473x | -92.99% |
| 2004-12-31 | $63.91 Million | $-15.67 Million | -0.245x | -383.43% |
| 2003-12-31 | $-150.23 Million | $-13.00 Million | 0.087x | -54.66% |
| 2002-12-31 | $-55.31 Million | $-10.55 Million | 0.191x | -- |
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more